Passage Bio, Inc. (PASG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Passage Bio, Inc. (PASG) closed at USD 3.66 on 2026-10-14, a change of -52.2 % over the past year, with a market capitalization of USD 11.58M.

Passage Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Passage Bio, Inc. key figures

Previous close

USD 3.66 (2026-10-14)

1-year change

-52.2 %

Market cap

USD 11.58M

Enterprise value

USD -12.57M

P/E ratio (trailing)

-0.32

P/E ratio (forward)

-0.35

EPS (trailing)

-11.30

EPS (forward)

-10.39

PEG ratio

n/a

Price to book

2.60

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.35

Employees

24

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Passage Bio, Inc.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Passage Bio, Inc. and compare it with other stocks.